Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.
Hoell JI, Ginzel S, Kuhlen M, Kloetgen A, Gombert M, Fischer U, Hein D, Demir S, Stanulla M, Schrappe M, Zur Stadt U, Bader P, Babor F, Schuster F, Strahm B, Alten J, Moericke A, Escherich G, von Stackelberg A, Thiele R, McHardy AC, Peters C, Bornhauser B, Bourquin JP, Krause S, Enczmann J, Meyer LH, Eckert C, Borkhardt A, Meisel R. Hoell JI, et al. Among authors: meyer lh. Blood Adv. 2019 Oct 22;3(20):3143-3156. doi: 10.1182/bloodadvances.2019000051. Blood Adv. 2019. PMID: 31648313 Free PMC article.
MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.
Boldrin E, Gaffo E, Niedermayer A, Boer JM, Zimmermann M, Weichenhan D, Claus R, Münch V, Sun Q, Enzenmüller S, Seyfried F, Demir S, Zinngrebe J, Cario G, Schrappe M, Den Boer ML, Plass C, Debatin KM, Te Kronnie G, Bortoluzzi S, Meyer LH. Boldrin E, et al. Among authors: meyer lh. Blood. 2021 Nov 18;138(20):1953-1965. doi: 10.1182/blood.2020007591. Blood. 2021. PMID: 34098582 Free article.
Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia.
Demir S, Boldrin E, Sun Q, Hampp S, Tausch E, Eckert C, Ebinger M, Handgretinger R, Kronnie GT, Wiesmüller L, Stilgenbauer S, Selivanova G, Debatin KM, Meyer LH. Demir S, et al. Among authors: meyer lh. Haematologica. 2020 Jan;105(1):170-181. doi: 10.3324/haematol.2018.199364. Epub 2019 May 9. Haematologica. 2020. PMID: 31073076 Free PMC article.
Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation.
Lázaro-Navarro J, Pimentel-Gutiérrez HJ, Gauert A, Hagemann AIH, Eisenschmid J, Gökbuget N, Vick B, Jeremias I, Seyfried F, Meyer LH, Debatin KM, Richer K, Bultman M, Neumann M, Hänzelmann S, Serve H, Astrahantseff K, Rieger MA, Eckert C, Baldus CD, Bastian L. Lázaro-Navarro J, et al. Among authors: meyer lh. Blood Adv. 2021 Dec 28;5(24):5501-5506. doi: 10.1182/bloodadvances.2021004513. Blood Adv. 2021. PMID: 34610112 Free PMC article. No abstract available.
Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling.
Seyfried F, Demir S, Hörl RL, Stirnweiß FU, Ryan J, Scheffold A, Villalobos-Ortiz M, Boldrin E, Zinngrebe J, Enzenmüller S, Jenni S, Tsai YC, Bornhauser B, Fürstberger A, Kraus JM, Kestler HA, Bourquin JP, Stilgenbauer S, Letai A, Debatin KM, Meyer LH. Seyfried F, et al. Among authors: meyer lh. Cell Death Dis. 2019 Jul 29;10(8):571. doi: 10.1038/s41419-019-1801-0. Cell Death Dis. 2019. PMID: 31358732 Free PMC article.
ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling.
Kuster L, Grausenburger R, Fuka G, Kaindl U, Krapf G, Inthal A, Mann G, Kauer M, Rainer J, Kofler R, Hall A, Metzler M, Meyer LH, Meyer C, Harbott J, Marschalek R, Strehl S, Haas OA, Panzer-Grümayer R. Kuster L, et al. Among authors: meyer c, meyer lh. Blood. 2011 Mar 3;117(9):2658-67. doi: 10.1182/blood-2010-03-275347. Epub 2011 Jan 11. Blood. 2011. PMID: 21224468 Free article.
Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways.
Meyer LH, Eckhoff SM, Queudeville M, Kraus JM, Giordan M, Stursberg J, Zangrando A, Vendramini E, Möricke A, Zimmermann M, Schrauder A, Lahr G, Holzmann K, Schrappe M, Basso G, Stahnke K, Kestler HA, Te Kronnie G, Debatin KM. Meyer LH, et al. Cancer Cell. 2011 Feb 15;19(2):206-17. doi: 10.1016/j.ccr.2010.11.014. Epub 2011 Feb 3. Cancer Cell. 2011. PMID: 21295523 Free article.
Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
Jebaraj BMC, Müller A, Dheenadayalan RP, Endres S, Roessner PM, Seyfried F, Walliser C, Wist M, Qi J, Tausch E, Mertens D, Fox JA, Debatin KM, Meyer LH, Taverna P, Seiffert M, Gierschik P, Stilgenbauer S. Jebaraj BMC, et al. Among authors: meyer lh. Blood. 2022 Feb 10;139(6):859-875. doi: 10.1182/blood.2021011516. Blood. 2022. PMID: 34662393 Free article.
56 results